Product
Ulixertinib
Aliases
BVD523, BVD-523, VRT752271
Name
Ulixertinib
10 clinical trials
1 drug
67 indications
Indication
TumorIndication
SolidIndication
Gastrointestinal CancerIndication
Pancreatic CancerIndication
Small Intestine CancerIndication
Colorectal CancerIndication
MelanomaIndication
Lung CancerIndication
Thyroid CancerIndication
Bladder CancerIndication
Head and Neck CancerIndication
Stomach CancerIndication
Esophageal cancerIndication
CholangiocarcinomaIndication
Ovarian CancerIndication
Hepatocellular CarcinomaIndication
GlioblastomaIndication
MAPK Gene MutationIndication
KRAS Activating MutationIndication
BRAF gene mutationIndication
NRASIndication
HRAS gene mutationIndication
MAP2K1 MutationIndication
ERK MutationIndication
Malignant NeoplasmIndication
Non-Hodgkin LymphomaIndication
Stage IV Non-Hodgkin LymphomaIndication
Histiocytic SarcomaIndication
Juvenile XanthogranulomaIndication
Langerhans Cell HistiocytosisIndication
Malignant GliomaIndication
Recurrent Childhood RhabdomyosarcomaIndication
EpendymomaIndication
Ewing SarcomaIndication
Recurrent GliomaIndication
HepatoblastomaIndication
Recurrent Langerhans Cell HistiocytosisIndication
Recurrent Malignant Germ Cell TumorIndication
Recurrent Malignant Solid NeoplasmIndication
MedulloblastomaIndication
NeuroblastomaIndication
OsteosarcomaIndication
Recurrent rhabdoid tumorIndication
Soft Tissue SarcomaIndication
GliomaIndication
Malignant Germ Cell TumorIndication
Malignant Solid NeoplasmIndication
Refractory Non-Hodgkin LymphomaIndication
Rhabdoid TumorIndication
RhabdomyosarcomaIndication
Soft Tissue Sarcoma AJCC v7Indication
Osteosarcoma AJCC v7Indication
Stage IV Soft Tissue Sarcoma AJCC v7Indication
Wilms tumorIndication
Histiocytic NeoplasmsIndication
Recurrent Ependymal TumorIndication
Histiocytic and Dendritic Cell NeoplasmIndication
Refractory Soft Tissue SarcomaIndication
Gastrointestinal NeoplasmsIndication
LymphomaIndication
Multiple MyelomaDrug
BVdClinical trial
A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced GI Malignancies Harboring Mitogen-activated Protein Kinase (MAPK) Pathway Mutations (BVD-523-HCQ)Status: Recruiting, Estimated PCD: 2024-12-06
Clinical trial
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesStatus:
Clinical trial
Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no BRAFV600 Mutations) MelanomaStatus: Recruiting, Estimated PCD: 2024-07-15
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening ProtocolStatus: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in AdultsStatus: Recruiting, Estimated PCD: 2025-09-22
Clinical trial
Phase 2 Trial of Ulixertinib for Patients With Histiocytic NeoplasmsStatus: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway MutationsStatus: Active (not recruiting), Estimated PCD: 2022-03-31
Clinical trial
A Phase I Trial of Ulixertinib (BVD-523) and Hydroxychloroquine in Patients With Advanced MAPK-Mutated Gastrointestinal AdenocarcinomasStatus: Completed, Estimated PCD: 2022-06-10
Clinical trial
MATCH Treatment Subprotocol Z1L: BVD-523FB (Ulixertinib) in Patients With Tumors With BRAF Fusions, or With Non-V600E, Non-V600K BRAF MutationsStatus: Active (not recruiting), Estimated PCD: 2025-03-24
Clinical trial
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed TherapyStatus: Recruiting, Estimated PCD: 2026-03-28